These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Trial is partly outside EEC, and reported results||2011-001953-10||A phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti D lentiviral vector for the treatment of cerebral adrenoleukodystrophy (CALD)||2021-03-26||bad-data|
|Exempt, with results||2012-000695-42||A Phase I/II Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Ce...||2019-02-26||not-yet-due|
|Other||2013-002245-11||Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector||not-yet-due|
|Other||2015-002805-13||Longterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product||not-yet-due|
|Listed as ongoing, but also has a completion date and reported results||2015-004122-33||A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent β- Thalassemia, who do not have β0/β0 Genotype, by Transplantation of Autologous C...||2022-03-31||bad-data|
|Ongoing||2016-003611-35||A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent β Thalassemia, who have a β0/β0 Genotype, by Transplantation of Autologous CD34+ St...||not-yet-due|
|Other||2018-001145-14||A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects inferior or equal to 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) St...||not-yet-due|
|Ongoing||2019-000331-63||A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.||not-yet-due|
|Ongoing||2019-004266-18||Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector||not-yet-due|